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Section 1:  HEAP Administrative Information 
Title Health Economic Analysis Plan (HEAP) for the TRIUMPH trial: a cluster randomised 
controlled trial to assess whether the use of non-pharmacological and non-surgical 
interventions improves lower urinary tract symptoms (LUTS) in men in primary healthcare 
Trial registration 
number; registry 
ISRCTN11669964 prospectively registered 12/04/2018; ISRCTN registry 
Source of 
funding 
National Institute for Health Research (NIHR), Health Technology Assessment 
Programme- Reference number 16/90/03  
Purpose of 
HEAP 
The purpose of the HEAP is to describe the analysis and reporting procedure intended for 
the economic analyses to be undertaken. The analysis plan is designed to ensure that 
there is no conflict with the protocol and associated statistical analysis plan (SAP), and it 
should be read in conjunction with them. 
Trial protocol 
version; date 
This document has been written based on information contained in the trial protocol 









HEAP revisions n/a 
Roles and 
responsibilities  
The HEAP was prepared by Dr Madeleine Cochrane (Junior Health Economist) and 
approved by Dr Sian Noble (Senior Health Economist). The trial health economists (Dr 
Madeleine Cochrane and Dr Sian Noble) are responsible for conducting and reporting the 
economic evaluation in accordance with the HEAP  
APPROVALS 
The following people have reviewed the Health Economics Analysis Plan and are in agreement with the 
contents. 
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Section 2: Trial Introduction & Background 
2.1 Trial Background and Rationale 
Lower-urinary tract symptoms (LUTS) in men, which can relate to storage or voiding, significantly 
impact on men’s quality of life (1-3). The UK’s National Institute for Health and Care Excellence 
(NICE) recommend that, after key assessments have been carried out, the initial treatment for LUTS 
should be conservative treatment (4). Assessing symptoms and offering conservative treatment is 
time-consuming and therefore challenging for GPs to fit within a single consultation. Consequently, 
conservative treatment may be ineffective in primary care, with men simply prescribed medication for 
their prostate, inappropriately referred to secondary care (5) or enduring persistent symptoms.  
2.2 Aim of the Trial 
To determine whether a care pathway including manualised and standardised application of non-
pharmacological and non-surgical interventions is superior to usual care, in terms of symptom severity 
reported one year after consent. 
2.3 Objectives of the trial 
The primary objective will be measured using overall International Prostate Symptom Score (IPSS) 
reported 12 months after consent. The secondary objectives of the trial are to compare the differences 
between comparator groups for the following outcomes:  
• Disease-specific quality of life (QoL) 
• Symptomatic outcomes  
• Relative harms  
• Cost-effectiveness 
• Use of NHS resources  
• Health-related QoL (HRQoL) and general health  
• Acceptability of assessment and care provided  
• Patients’ perceptions on their LUTS condition  
2.4 Trial population 
Thirty National Health Service (NHS) General Practice (GP) sites (comprising 32 GP practices) from 
the UK’s West of England and Wessex Clinical Research Network (CRN) regions took part in the study. 
GP practices were eligible to take part in the trial if they had an adequate number of potentially eligible 
patients and treatment-room space for intervention delivery.  Where possible, sites were selected to 
achieve a range in patient list size, deprivation score and preference on whether existing practice staff 
or a trial research nurse delivered the intervention. Males ≥18 years old, who considered themselves to 
have bothersome LUTS and who had presented to primary care with at least one symptom of LUTS 
within the last 5 years were invited to take part in the trial if they did not meet any of the exclusion 
criteria.  
 




2.5 Intervention and comparators 
TRIUMPH is a conservative intervention for treating LUTS, involving the provision of a standardised 
booklet with information and active management advice for men in primary care presenting with LUTS. 
The intervention includes a manualised care component where participants receive consultations from 
one of four healthcare professionals (HCPs): GP practice clinical nurse, GP research nurse, healthcare 
assistant or dedicated trial research nurse. All HCPs received training on intervention delivery and are 
invited to attend ongoing HCP teleconferences to support the initial training.   
The HCP carries out basic assessments in order to understand the patient’s personal circumstances, 
symptom needs and the impact the patient’s symptoms are having on their QoL. The HCP directs 
patients to the most applicable information and advice in the booklet.  The HCP then conducts follow 
up contacts with the patient at 1 week (phone), 4 and 12 weeks (phone, text or email depending on 
patient preference) after receiving the intervention to offer encouragement and support. The comparator 
group is usual care in standard practice, which may vary between GP Practices.   
2.6 Trial design 
The TRIUMPH trial is a pragmatic, two-arm, cluster RCT where clusters are randomised at the level of 
the GP practices 1:1 between the intervention arm (standardised and manualised care intervention) 
and control group (usual care). Randomisation is minimised by centre (Bristol and Southampton), size 
of GP practice (number of registered patients at a practice) and level of deprivation (Index of Multiple 
Deprivation score based on the postcode of the GP practice). Power for the study is based on the 
primary outcome, which is to detect a clinical improvement in overall IPSS score of 2. IPSS is a patient-
reported questionnaire, which will be completed at baseline, and 6 and 12 months after consent. 
Secondary outcomes measured through patient-reported questionnaires will be completed 6 and 12 
months after consent. Primary-care medical records will be extracted at 12 months only. The senior 
statistician and senior health economist will be blinded throughout the trial. The junior trial statistician 
and health economist will conduct disaggregated analyses based on pre-specified analysis plans.  
 
2.7 Trial start and end dates 
Recruitment of the GP practices commenced in May 2018 and the first patient was recruited on 31th 
July 2018. The internal four-month pilot phase of recruitment was completed on 10th November 2018, 
while recruitment for the main trial ended at the start of August 2019. The 12-month follow up period 
ends August 2020 with the study closing in May 2021.   
 
Section 3: Economic Approach 
3.1 Aims of economic evaluation 
The aim of the economic evaluation is to answer the following research question: “What is the within-
trial cost-effectiveness of a manualised and standardised non-pharmacological intervention to treat 
men presenting in primary care with LUTS compared to usual care?”    
 




3.2 Objective of the economic evaluation 
The primary objective of the economic evaluation is to estimate the within-trial cost-effectiveness at 
12-month follow up of a manualised and standardised non-pharmacological intervention versus usual 
care for patients experiencing bothersome LUTS.  
3.3 Overview of economic analysis 
Cost-effectiveness will be assessed using individual patient-level data from the TRIUMPH study. The 
Net Benefit (NB) framework will be used to assess cost-effectiveness over a range of values for the 
QALY including the UK’s cost-effectiveness threshold (£20,000-£30,000 per QALY). In order to 
calculate a robust estimate of the expected NB, between group differences in costs and QALYs will 
be evaluated using appropriate regression techniques (e.g. multilevel modelling). Uncertainty in the 
results will be addressed using cost-effectiveness acceptability curves and sensitivity analyses. A 
secondary analysis will examine the between group difference in costs and IPSS score. If neither arm 
is dominant (i.e. both cheaper and more effective), then an incremental cost-effectiveness ratio 
(ICER) will be calculated in relation to the IPSS score.  
3.4 Jurisdiction 
The trial will be conducted in the UK where the health system is publicly funded and is free at the 
point of access. 
3.5 Perspectives 
All economic analyses will be conducted from the NHS perspective.  
3.6 Time horizon 
All analyses will compare costs and outcomes over the trial time horizon which will be from baseline 
to 12 months after patient consent.  
Section 4: Economic Data Collection and Management 
4.1 Statistical software use for health economic analysis 
Stata version 16.1 or higher will be used for all health economic analyses. 
4.2 Identification of resources 
Relevant NHS resources identified as important include: (1) resources used for the training and 
delivery of the TRIUMPH intervention; and (2) Primary and secondary health care use. Primary health 
care includes consultations with key healthcare professionals (e.g. GP, Nurse and Healthcare 
Assistant). Primary care prescriptions include all LUTS-related medication. Secondary care use 
includes LUTS-related outpatient, day case, inpatient and accident and emergency (A&E) visits.  
4.3 Measurement of resource use data 
Intervention training and delivery costs 
 




Resource use relating to training staff to deliver the intervention and ongoing support for staff 
delivering the intervention in the form of HCP teleconferences will be recorded by the research team. 
Data will include: type of staff, duration of training and travel expenses. Intervention delivery 
resources include resources which are standardised across patients (e.g. one intervention booklet per 
patient, an in-person consultation at week 0 and a phone consultation at week 1) and those which 
vary between patients (e.g. type of HCP, time to deliver consultations at week 0, 1, 4 and 12). HCPs 
will be asked to record this information at the end of each patient consultation in a case report form 
(CRF). In addition, in the week 4 and 12 CRFs, HCPs will be asked to record mode of delivery 
(phone, text, email).  
Primary and secondary health care use 
Health care resource use is being captured for: (1) all types of primary care consultations; (2) LUTS 
related prescribed medication; and (3) LUTS-related secondary care activity (e.g. outpatient, day 
case, inpatient and A&E visits). Information on primary care consultations and LUTS-related 
medications will be extracted from GP electronic medical records (EMRs). Secondary care LUTS 
related health care use will be obtained from self-completed questionnaires, administered either 
electronically or via a postal questionnaire.  If deemed necessary, this information will be 
supplemented by information received by GP practices from hospitals (e.g. secondary care letters). 
4.4 Valuation of resource use data 
All primary and community healthcare resource use identified and measured will be valued in 
monetary terms in 2018/19 costs using the latest Unit Cost series by the Personal Social Services 
Research Unit (PSSRU) (6). Secondary healthcare resource use will be valued using NHS costs from 
the 2018/19 National Cost Collection (7). Prescribed medications will be assigned a unit cost from the 
British National Formulary (BNF) (8) or Prescription Cost Analysis (9); When a unit cost is not 
available for the year of analysis, it will be inflated to current prices using the NHS cost inflation index 
(NHSCII) as published in the Unit Cost series (6). 
4.5 Identification of outcomes 
The primary economic outcome measure will be Quality Adjusted Life Years (QALYs) derived from 
utility scores, obtained using the EQ-5D-5L quality of life instrument. The primary outcome from the 
clinical effectiveness evaluation, the IPSS, will be reported as a secondary outcome in the economic 
evaluation. 
4.6 Measurement of outcomes 
Outcomes will be collected at baseline, 6- and 12- months post consent, using a participant self-
completed questionnaire. At baseline the questionnaire was administered via post, at 6- and 12- 
month follow up it could be completed online or via post.  
 




4.7 Valuations of outcomes 
Patients’ EQ-5D-5L profiles will be mapped to the EQ-5D-3L valuation set using a validated mapping 
function by van Hout et al. (10) as recommended by National Institute for Health and Care Excellence 
(NICE). The valuation set enables a utility score to be calculated for each patient based on published 
UK population utility values. The area-under-the-curve approach will be used to transform the utility 
scores into QALYs for the 12-month time horizon. IPSS scores will be reported in their natural units 
(not monetised). 
Section 5: Economic Data Analysis 
5.1 Analysis population 
All patients who did not withdraw their consent will be analysed according to the randomised 
allocation of their GP practice. 
5.2 Timing of analyses 
The final analysis will be conducted at the end of the trial, which will be 12 months post consent.  
5.3 Discount rates for costs and benefits 
As costs and benefits will not be assessed beyond 12 months post consent discounting will not be 
required.  
5.4 Cost-effectiveness threshold(s) 
Adjusted mean costs and QALYs associated with each comparator group will be combined through 
the NB framework. Cost-effectiveness will be evaluated using the NB framework over a range of 
values for the QALY, including the UK NICE recommended cost-effectiveness thresholds of £20,000-
30,000 per QALY.  
5.9 Data cleaning for analysis 
The EMR will come from two different GP systems: EMIS and SystmOne. A SOP will be created to 
ensure that the final analysis dataset will be comparable across the two GP systems. 
5.10 Missing data 
Missing data will be handled depending upon the prevalence and likely cause of the missingness. The 
mechanism of missingness will be assessed.  For example, if the data is believed to be missing at 
random (MAR), then multiple imputation methods may be used.  
5.7 Analysis of resource use and costs  
Mean resource use will be estimated and presented by trial arm for each resource use category (e.g. 
outpatient visits, medication use, etc.). Standard deviations (SD) and the number of patients included 
in each category by arm will also be presented. Appropriate regression techniques will be used to 
estimate adjusted mean costs and the difference in adjusted mean costs (and their associated 95% 
confidence intervals) between the trial arms. In order to take into account the cluster design nature of 
 




the trial, multilevel modelling (MLM) will be used (i.e. to account for the correlation between patients 
from the same cluster- GP practice) (11-13). The MLM will adjust for the prespecified covariates used 
in the minimisation process (e.g. centre, practice size, area-level deprivation). In addition, type of GP 
system for EMRs will also be controlled for in the analysis. The multiple levels of the model include 
the individual patients (level 1) and the GP practices (level 2). Model choice for the MLM will be 
guided by examination of the residuals from the fixed and random parts. Alternative methods of 
analysis will be considered if the assumptions of the model are not be met. If costs are not normally 
distributed, they may need to be modelled with a gamma distribution through multilevel mixed-effects 
generalised linear modelling.  
5.8 Analysis of outcomes  
The primary economic outcome in the economic evaluation is Quality-Adjusted Life Years (QALYs). 
QALYs for each patient over the 12-month period will be calculated from the utility values using the 
area under the curve approach. Appropriate regression techniques such as MLM will be used to 
estimate adjusted mean QALYs and the difference in adjusted mean QALYs (and their associated 
95% confidence intervals) between the trial arms taking into account the cluster design of the study 
(11-13). The MLM will adjust for the prespecified covariates used in the minimisation process (e.g. 
centre, practice size, area-level deprivation) and baseline utility (14). The multiple levels of the model 
include the individual patients (level 1) and the GP practices (level 2). The secondary outcome 
analysis will draw on the between group difference in mean IPSS score reported 12 months post 
consent as described in the SAP.   
5.11 Analysis of cost-effectiveness 
If neither arm is dominant (i.e. less expensive and more effective), incremental cost-effectiveness 
ratios (ICERs) will be created using the outputs from the appropriate regression. These outputs will 
also be used to estimate the incremental net monetary benefit (INMB) statistic at the standard NICE 
willingness to pay thresholds of both £20,000 and £30,000 per QALY. A secondary analysis will 
examine mean differences in IPSS score with mean differences in costs. If neither the intervention or 
usual care group is dominant (e.g. less expensive and more effective) then an ICER will be 
calculated, reporting the incremental cost per unit change in IPSS score. 
5.12 Sampling uncertainty 
Uncertainty will be addressed using cost-effectiveness acceptability curves for a range of willingness-
to-pay thresholds. This assesses the probability of the intervention being the cost-effective option at a 
range of willingness-to-pay thresholds.    
5.13 Subgroup analyses/Analysis of heterogeneity 
An analysis will be performed in which patients who completed follow-up from 11th March 2020 (where 
11th March 2020 refers to the date when the World Health Organisation declared the COVID-19 
outbreak as a pandemic) will be compared to those who completed follow-up before this data. 
 




5.14 Sensitivity Analyses 
Uncertainty in the methodological choices made for the present economic evaluation will be assessed 
through a number of sensitivity analyses. This will involve making plausible changes to key 
methodological assumptions in order to understand how changes in the methodological assumption 
impacts of the cost-effectiveness result. Examples include: 
• Inclusion/ exclusion of training and ongoing support costs 
• Assuming intervention visits are/are not logged in the GP records 
• Assuming all consultations had the same unit cost per healthcare professional type 
(regardless of mode of delivery) 
• If applicable, different approaches to the handling of missing data 
Section 6: Reporting/Publishing 
6.1 Reporting standards 
The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guidelines will be 
followed when reporting the health economic evaluation, in a format appropriate to stakeholders and 
policy makers. 
6.2 Reporting deviations from the HEAP 
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